NYSE:OGEN Oragenics (OGEN) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free OGEN Stock Alerts $1.41 +0.01 (+0.71%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.26▼$1.4550-Day Range$1.40▼$6.1452-Week Range$1.26▼$7.74Volume217,127 shsAverage Volume155,650 shsMarket Capitalization$6.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Oragenics alerts: Email Address Ad Weiss RatingsThe ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About OragenicsOragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More OGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OGEN Stock News HeadlinesMarch 18, 2024 | markets.businessinsider.comOragenics Appoints Kelly As Chief Medical OfficerMarch 17, 2024 | finance.yahoo.com15 Highest Quality Probiotics For Gut HealthMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 15, 2024 | americanbankingnews.comOragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.comMarch 5, 2024 | businesswire.comOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionMarch 1, 2024 | businesswire.comOragenics Announces Closing of Public OfferingMarch 1, 2024 | uk.investing.comOragenics announces public stock offeringFebruary 28, 2024 | investorplace.comWhy Is Oragenics (OGEN) Stock Down 45% Today?March 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 27, 2024 | markets.businessinsider.comOragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock PlungesFebruary 27, 2024 | businesswire.comOragenics Announces Pricing of Public OfferingFebruary 27, 2024 | marketwatch.comOragenics Shares Fall After Proposed Public OfferingFebruary 27, 2024 | businesswire.comOragenics Announces Proposed Public OfferingFebruary 12, 2024 | marketwatch.comOragenics CEO Murphy Leaves, President Redmond Named Interim ReplacementFebruary 12, 2024 | finance.yahoo.comOragenics, Inc. Announces Leadership TransitionFebruary 7, 2024 | finance.yahoo.comOragenics, Inc. Announces Expiration of Its Investment Banking Engagement AgreementFebruary 5, 2024 | finance.yahoo.comOragenics, Inc. Preparing for Phase II Clinical Trials to Treat ConcussionJanuary 23, 2024 | msn.comOragenics terminates ATM offering program; shares jumpJanuary 23, 2024 | finance.yahoo.comOragenics Announces Termination of At-The-Market Offering ProgramJanuary 6, 2024 | seekingalpha.comOGEN, RLMD and ATXI among mid-day moversJanuary 2, 2024 | financialpost.comOragenics Completes Acquisition of Odyssey Health’s Neurological AssetsDecember 12, 2023 | finanznachrichten.deOdyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.November 6, 2023 | finance.yahoo.comOragenics, Inc. (UAV.F)November 2, 2023 | finance.yahoo.comOragenics Issues Update to ShareholdersOctober 5, 2023 | marketwatch.comOragenics Shares Rise 15% After Deal to Buy Some Odyssey Health AssetsOctober 5, 2023 | finance.yahoo.comOragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug CandidateOctober 2, 2023 | msn.comOragenics, AVITA Medical among healthcare moversSee More Headlines Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2021Today3/19/2024Next Earnings (Estimated)4/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net MarginsN/A Pretax Margin-26,700.00% Return on Equity-132.48% Return on Assets-93.84% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$130,000.00 Price / Sales48.59 Cash FlowN/A Price / Cash FlowN/A Book Value$5.64 per share Price / Book0.25Miscellaneous Outstanding Shares4,480,000Free Float3,379,000Market Cap$6.32 million OptionableN/A Beta0.29 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Joseph Michael Redmond (Age 63)President & Interim Principal Executive Officer Ms. Janet Huffman (Age 52)CFO, Secretary & Treasurer Key CompetitorsPulmatrixNASDAQ:PULMKinetaNASDAQ:KAGenprexNASDAQ:GNPXHillstream BioPharmaNASDAQ:HILSNexImmuneNASDAQ:NEXIView All CompetitorsInsidersFred TellingSold 3,500 sharesTotal: $12,495.00 ($3.57/share)View All Insider Transactions OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed in 2024? Oragenics' stock was trading at $6.1382 on January 1st, 2024. Since then, OGEN shares have decreased by 77.0% and is now trading at $1.41. View the best growth stocks for 2024 here. When is Oragenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, April 12th 2024. View our OGEN earnings forecast. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSE:OGEN) released its quarterly earnings data on Monday, August, 16th. The company reported ($1.80) EPS for the quarter, topping the consensus estimate of ($2.40) by $0.60. When did Oragenics' stock split? Oragenics's stock reverse split before market open on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ), MFA Financial (MFA) and Inpixon (INPX). How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:OGEN) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.